New Targets Show Bayer Is Doing Better
November 25, 2004Advertisement
German chemicals and pharmaceuticals giant Bayer upgraded its full-year targets slightly on Thursday after its third-quarter earnings came in better than expected, thanks to the favorable performance of its chemicals businesses. Bayer, best known for its Aspirin pain killer, said in a
statement it had earned a total 34 million euros (45 million
dollars) after tax in the period from July to September, compared with a loss of 123 million euros a year earlier. Sales were up 3.4 percent at 7.065 billion euros. Credit went to the company's agrochemical, industrial chemicals, and high performance plastics and polymer divisions. The three offset the lagging sales of the anti-bacterial medicine Cipro. (AFP)
statement it had earned a total 34 million euros (45 million
dollars) after tax in the period from July to September, compared with a loss of 123 million euros a year earlier. Sales were up 3.4 percent at 7.065 billion euros. Credit went to the company's agrochemical, industrial chemicals, and high performance plastics and polymer divisions. The three offset the lagging sales of the anti-bacterial medicine Cipro. (AFP)